Literature DB >> 29789917

Comparison of Clinical Profiles in Patients with Protein-Losing Enteropathy With and Without Fontan Circulation.

Shin Ono1, Hideo Ohuchi2, Aya Miyazaki1, Osamu Yamada1.   

Abstract

Protein-losing enteropathy (PLE) is a life-threatening complication in patients following the Fontan operation. However, PLE also develops in some patients with congenital heart disease (CHD) after biventricular repair (BVR). This study compared clinical profiles of PLE patients following the Fontan operation with those after BVR. We retrospectively reviewed clinical charts of postoperative CHD patients with PLE. The study population comprised 42 PLE patients (14BVR, 28Fontan). Postoperative follow-up period until onset was significantly shorter in the Fontan group than in the BVR group (14 ± 2 vs. 8 ± 1 years, p = 0.02), while there was no difference in PLE onset age between groups. Furthermore, there were no differences in prevalence of clinically relevant arrhythmias, cardiac output, or central venous pressure between the two groups at PLE onset. Percentage of structural lesions (valve regurgitation and/or stenotic lesions) responsible for development of PLE and ventricular end-diastolic pressure were higher in the BVR group than in the Fontan group (93 vs. 50%, p < 0.01), (13.4 ± 6.3 vs. 7.5 ± 4.1, p < 0.0001). Catheter intervention was applied in 2Fontan and 6BVR patients, while surgical intervention was required in 8BVR and 7Fontan patients. Of these, catheter intervention was effective in 2 (25%, 1Fontan, 1BVR) and surgical intervention was effective in 4 (26.7%, 1Fontan, 3BVR). Only one patient (5.3%) improved without intervention. Complete PLE remission rate was higher in the BVR group than in the Fontan group (38 vs. 7%, p = 0.02). During follow-up, death of 2 BVR and 8 Fontan patients occurred. There were no group differences in 5- to 10-year survival rates after PLE onset (81 vs. 81%, BVR, 81 vs. 66%, Fontan). Although BVR patients may have greater chance of PLE remission when compared with those exhibiting Fontan pathophysiology, mortality in PLE-CHD patients was significantly high regardless of postoperative hemodynamics.

Entities:  

Keywords:  Biventricular repair; Congenital heart disease; Fontan; Protein losing enteropathy

Mesh:

Year:  2018        PMID: 29789917     DOI: 10.1007/s00246-018-1893-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

1.  Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.

Authors:  William A Zoghbi; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Carol D Kraft; Robert A Levine; Petros Nihoyannopoulos; Catherine M Otto; Miguel A Quinones; Harry Rakowski; William J Stewart; Alan Waggoner; Neil J Weissman
Journal:  J Am Soc Echocardiogr       Date:  2003-07       Impact factor: 5.251

2.  Protein-losing gastroenteropathy in congestive heart-failure.

Authors:  J D DAVIDSON; T A WALDMANN; D S GOODMAN; R S GORDON
Journal:  Lancet       Date:  1961-04-29       Impact factor: 79.321

3.  Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association.

Authors:  Timothy F Feltes; Emile Bacha; Robert H Beekman; John P Cheatham; Jeffrey A Feinstein; Antoinette S Gomes; Ziyad M Hijazi; Frank F Ing; Michael de Moor; W Robert Morrow; Charles E Mullins; Kathryn A Taubert; Evan M Zahn
Journal:  Circulation       Date:  2011-05-02       Impact factor: 29.690

4.  Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group.

Authors:  L Mertens; D J Hagler; U Sauer; J Somerville; M Gewillig
Journal:  J Thorac Cardiovasc Surg       Date:  1998-05       Impact factor: 5.209

5.  Haemodynamic characteristics before and after the onset of protein losing enteropathy in patients after the Fontan operation.

Authors:  Hideo Ohuchi; Kenji Yasuda; Aya Miyazaki; Masataka Kitano; Heima Sakaguchi; Satoshi Yazaki; Etsuko Tsuda; Osamu Yamada
Journal:  Eur J Cardiothorac Surg       Date:  2013-03       Impact factor: 4.191

6.  Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis.

Authors:  P Wilkinson; B Pinto; J R Senior
Journal:  N Engl J Med       Date:  1965-11-25       Impact factor: 91.245

Review 7.  ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.

Authors:  Robert O Bonow; Blase A Carabello; Chatterjee Kanu; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-08-01       Impact factor: 29.690

8.  Protein-losing enteropathy after the Fontan operation.

Authors:  R H Feldt; D J Driscoll; K P Offord; R H Cha; J Perrault; H V Schaff; F J Puga; G K Danielson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-09       Impact factor: 5.209

9.  Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy.

Authors:  C Müller; S Globits; D Glogar; W Klepetko; P Knoflach
Journal:  Eur Heart J       Date:  1991-10       Impact factor: 29.983

10.  Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation.

Authors:  Anitha S John; Jennifer A Johnson; Munziba Khan; David J Driscoll; Carole A Warnes; Frank Cetta
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.